N-Cycloheptyl-N'-(3-fluoro-4-methyl-phenyl)-N''-methyl-N''-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine | 676354-33-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Cycloheptyl-N'-(3-fluoro-4-methyl-phenyl)-N''-methyl-N''-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine
• 英文别名: 4-N-cycloheptyl-6-N-(3-fluoro-4-methylphenyl)-2-N-methyl-2-N-(1-methylpiperidin-4-yl)-1,3,5-triazine-2,4,6-triamine
• CAS: 676354-33-9
• 化学式: C₂₄H₃₆FN₇
• 分子量: 441.595
• InChiKey: ASDGZWQSZJRVEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  69.2
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  1-甲基-4-(甲氨基)哌啶 、 6-Chloro-N-cycloheptyl-N'-(3-fluoro-4-methyl-phenyl)-[1,3,5]triazine-2,4-diamine 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 以25%的产率得到N-Cycloheptyl-N'-(3-fluoro-4-methyl-phenyl)-N''-methyl-N''-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4,6-triamine
  参考文献：
  名称：

  Triazine compounds and their analogs, compositions, and methods

  摘要：

  本发明涉及三嗪化合物及其类似物和衍生物，以及包含这些化合物的方法和组合物。本发明的化合物和组合物可用于治疗由炎症反应引起的病理生理条件，抑制或阻断糖化蛋白诱导内皮细胞中与信号相关的炎症反应，抑制平滑肌增殖，治疗以平滑肌增殖为特征的血管闭塞性疾病，如再狭窄和动脉粥样硬化等。

  公开号：

  US20050227983A1

文献信息

• [EN] METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS<br/>[FR] METHODES ET COMPOSITIONS A BASE DE NOUVEAUX COMPOSES DE TRIAZINE
  申请人：REDDY US THERAPEUTICS INC

  公开号：WO2004026844A1

  公开（公告）日：2004-04-01

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及包含治疗由炎症反应引起的病理生理状况的化合物的方法和组合物。特别是，本发明涉及抑制或阻断在内皮细胞中由糖化蛋白产生的与信号传递相关的炎症反应的化合物。本发明还涉及抑制平滑肌细胞增殖的化合物。特别是，本发明涉及通过调节诸如Perlecan的HSPGs来抑制平滑肌细胞增殖的化合物。本发明进一步涉及使用化合物来治疗由平滑肌增殖特征的心血管闭塞性状况，如再狭窄和动脉粥样硬化。
• Methods and compositions of novel triazine compounds
  申请人：——

  公开号：US20040224950A1

  公开（公告）日：2004-11-11

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及包含治疗由炎症反应引起的病理生理状况的化合物的方法和组合物。特别是，本发明旨在使用化合物来抑制或阻断在内皮细胞中由糖化蛋白产生的与信号传导相关的炎症反应。本发明还涉及抑制平滑肌增殖的化合物。特别是，本发明旨在使用通过调节如Perlecan之类的HSPGs来抑制平滑肌细胞增殖的化合物。本发明进一步涉及使用化合物来治疗由平滑肌增殖特征的心血管闭塞性状况，如再狭窄和动脉粥样硬化。
• [EN] SUBSTITUTED UREA-OCTAHYDROINDOLS AS ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR 1 (MCH1R)<br/>[FR] UREE-OCTAHYDROINDOLES SUBSTITUES UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR 1 DE L'HORMONE DE CONCENTRATION DE LA MELANINE (MCH1R)
  申请人：BIOVITRUM AB

  公开号：WO2005051380A1

  公开（公告）日：2005-06-09

  The invention relates to compounds of the general formula (I). (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, and X are as defined in the description, or pharmaceutically acceptable salts, hydrates, geometrical isomers, racemates, tautomers, optical isomers, N-oxides and prodrug forms thereof. The compounds may be used for the treatment or prophylaxis of disorders related to the MCH1R receptor and for modulation of appetite. The invention also relates to such use as well as to pharmaceutical formulations comprising a compound of formula (I).

  该发明涉及通式（I）的化合物。其中R1、R2、R3、R4、R5、R6、R7、R8和X如描述中所定义，或药用盐、水合物、几何异构体、拉克酸盐、互变异构体、光学异构体、N-氧化物及其前药形式。这些化合物可用于治疗或预防与MCH1R受体相关的疾病，并用于调节食欲。该发明还涉及该用途以及包含通式（I）化合物的药物配方。
• Medical devices employing triazine compounds and compositions thereof
  申请人：Timmer T. Richard

  公开号：US20070122444A1

  公开（公告）日：2007-05-31

  The present invention relates to methods, compounds, and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses, and is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention also relates to compounds that inhibit smooth muscle proliferation, for example, by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis. This invention also relates to medical devices, such as a stent, comprising a compound or composition of this invention disposed on or within the medical device.

  本发明涉及用于治疗由炎症反应引起的病理生理条件的方法、化合物和组合物，其针对的是抑制或阻断糖基化蛋白诱导的内皮细胞信号相关炎症反应的化合物。本发明还涉及抑制平滑肌增殖的化合物，例如通过调节HSPGs（如Perlecan）来实现。本发明进一步涉及使用化合物来治疗由平滑肌增殖所特征的血管闭塞性疾病，例如再狭窄和动脉粥样硬化。本发明还涉及医疗器械，例如支架，其包括本发明的化合物或组合物在医疗器械上或内部安置。
• METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS
  申请人：Reddy US Therapeutics, Inc.

  公开号：EP1560817A1

  公开（公告）日：2005-08-10